ANI Pharmaceuticals (NASDAQ:ANIP) VP Meredith Cook Sells 500 Shares

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the completion of the sale, the vice president directly owned 74,424 shares in the company, valued at approximately $5,617,523.52. The trade was a 0.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Monday, July 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $81.84, for a total value of $40,920.00.
• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total value of $41,015.00.

ANI Pharmaceuticals Stock Down 0.5%

ANIP stock opened at $74.77 on Friday. The company’s 50 day moving average is $80.91 and its 200 day moving average is $79.05. The stock has a market cap of $1.70 billion, a price-to-earnings ratio of 16.11 and a beta of 0.44. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 1-year low of $70.15 and a 1-year high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same period in the previous year, the business posted $1.80 earnings per share. ANI Pharmaceuticals’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ANIP. Canaccord Genuity Group dropped their price objective on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a report on Monday. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim dropped their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday. Finally, Weiss Ratings cut ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $105.83.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ANIP. KBC Group NV bought a new stake in shares of ANI Pharmaceuticals in the 1st quarter worth approximately $28,000. Advisors Asset Management Inc. purchased a new stake in shares of ANI Pharmaceuticals in the 1st quarter valued at $28,000. Hantz Financial Services Inc. grew its holdings in shares of ANI Pharmaceuticals by 70.3% during the 4th quarter. Hantz Financial Services Inc. now owns 603 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 249 shares during the last quarter. Kemnay Advisory Services Inc. bought a new position in shares of ANI Pharmaceuticals during the 4th quarter valued at $48,000. Finally, State of Wyoming purchased a new position in ANI Pharmaceuticals in the 2nd quarter worth $50,000. 76.05% of the stock is currently owned by institutional investors.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.